Wall Street brokerages predict that Antares Pharma, Inc. (NASDAQ:ATRS) will announce ($0.03) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Antares Pharma’s earnings, with estimates ranging from ($0.04) to ($0.01). Antares Pharma also reported earnings of ($0.03) per share in the same quarter last year. The company is scheduled to report its next quarterly earnings report on Tuesday, March 13th.
According to Zacks, analysts expect that Antares Pharma will report full year earnings of ($0.11) per share for the current year, with EPS estimates ranging from ($0.12) to ($0.10). For the next year, analysts expect that the company will report earnings of $0.00 per share, with EPS estimates ranging from ($0.11) to $0.18. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Antares Pharma.
Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings results on Tuesday, November 7th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03). Antares Pharma had a negative return on equity of 57.34% and a negative net margin of 36.22%. The company had revenue of $15.10 million for the quarter, compared to analysts’ expectations of $14.01 million. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year.
A number of analysts have recently weighed in on the company. HC Wainwright set a $5.00 price objective on Antares Pharma and gave the stock a “buy” rating in a research report on Friday, October 13th. Piper Jaffray Companies set a $3.00 price objective on Antares Pharma and gave the stock a “buy” rating in a research report on Monday, October 23rd. Finally, ValuEngine lowered Antares Pharma from a “hold” rating to a “sell” rating in a report on Monday, October 16th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and two have issued a strong buy rating to the company’s stock. Antares Pharma has a consensus rating of “Buy” and a consensus target price of $3.84.
In other Antares Pharma news, Director Leonard S. Jacob sold 230,000 shares of the firm’s stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $4.05, for a total transaction of $931,500.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Thomas J. Garrity sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, October 3rd. The stock was sold at an average price of $3.50, for a total value of $105,000.00. The disclosure for this sale can be found here. Company insiders own 11.60% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in ATRS. Vanguard Group Inc. lifted its position in Antares Pharma by 10.1% in the second quarter. Vanguard Group Inc. now owns 6,186,232 shares of the specialty pharmaceutical company’s stock valued at $19,920,000 after purchasing an additional 567,144 shares during the period. Perceptive Advisors LLC lifted its position in Antares Pharma by 2.0% in the third quarter. Perceptive Advisors LLC now owns 4,353,897 shares of the specialty pharmaceutical company’s stock valued at $14,107,000 after purchasing an additional 86,644 shares during the period. State Street Corp lifted its position in Antares Pharma by 2,682.1% in the second quarter. State Street Corp now owns 2,027,650 shares of the specialty pharmaceutical company’s stock valued at $6,530,000 after purchasing an additional 1,954,769 shares during the period. JW Asset Management LLC lifted its position in Antares Pharma by 27.7% in the second quarter. JW Asset Management LLC now owns 1,671,956 shares of the specialty pharmaceutical company’s stock valued at $5,384,000 after purchasing an additional 362,431 shares during the period. Finally, Northern Trust Corp lifted its position in Antares Pharma by 478.1% in the second quarter. Northern Trust Corp now owns 1,654,266 shares of the specialty pharmaceutical company’s stock valued at $5,327,000 after purchasing an additional 1,368,131 shares during the period. Institutional investors and hedge funds own 34.63% of the company’s stock.
Antares Pharma (NASDAQ ATRS) traded down $0.03 during trading on Friday, hitting $1.99. The stock had a trading volume of 1,249,239 shares, compared to its average volume of 1,521,937. Antares Pharma has a 1-year low of $1.58 and a 1-year high of $4.09. The company has a debt-to-equity ratio of 0.69, a quick ratio of 2.89 and a current ratio of 3.34.
COPYRIGHT VIOLATION WARNING: “Analysts Anticipate Antares Pharma, Inc. (ATRS) to Announce -$0.03 EPS” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/01/11/analysts-anticipate-antares-pharma-inc-atrs-to-announce-0-03-eps.html.
About Antares Pharma
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Get a free copy of the Zacks research report on Antares Pharma (ATRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.